Back to first-pass browser

First-pass extracted concept

nanoparticle-based drug delivery systems

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

nanoparticle (NP)-based DDSs, NP-based DDSs

Extracted Explainers

What the tool is doing

Nanoparticle-based drug delivery systems are described as delivery platforms that help treatments reach intended targets while minimizing adverse effects. In this review they are emphasized as carriers for siRNA therapeutics in ovarian cancer.

Source 1DOIPubMed

Resources required

The abstract states that synthesis techniques and modification of physical and chemical nanoparticle properties are important for effective targeting. It also frames 3D tumor models as useful evaluation systems for tumor penetration.

Source 1DOIPubMed

What problem it solves

These systems are presented as a way to improve stability, controlled release, and toxicity profiles of therapeutics, especially siRNA-based treatments for ovarian cancer. They are also positioned as a strategy to address treatment resistance.

Source 1DOIPubMed

What it does not solve

The abstract indicates that clinical application of siRNA-based drugs still requires further study and refinement. It therefore does not present nanoparticle DDSs as a fully solved translational problem.

Source 1DOIPubMed

Alternatives

The abstract contrasts these systems mainly with conventional treatments, describing siRNA-based DDS approaches as complementary rather than outright replacements.

Source 1DOIPubMed

Evidence Snippets

nanoparticle (NP)-based DDSs have shown remarkable potential in oncology, particularly for ovarian cancer (OC)
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1capabilitysupports2026Source 1DOIPubMed

Nanoparticle-based drug delivery systems have shown potential in oncology, particularly for ovarian cancer.

Quoted textsource-backed
nanoparticle (NP)-based DDSs have shown remarkable potential in oncology, particularly for ovarian cancer (OC)
Claim 2engineering principlesupports2026Source 1DOIPubMed

Modifying the physical and chemical properties of nanoparticles can improve their ability to target cancer cells effectively.

Quoted textsource-backed
modifying their physical and chemical properties can improve their ability to target cancer cells effectively
Claim 3mechanistic advantagesupports2026Source 1DOIPubMed

Various nanoparticle platforms can enhance drug stability, enable controlled release, and reduce toxicity.

Quoted textsource-backed
We review various NP platforms shedding light on how they enhance drug stability, enable controlled release, and reduce toxicity.
Claim 4model system utilitysupports2026Source 1DOIPubMed

3D tumor models more accurately replicate real tumor complexity and can be used to examine nanoparticle tumor penetration and therapy delivery in realistic settings.

Quoted textsource-backed
3D-tumor models, which more accurately replicate the complexity of real tumors. This enables us to examine the ability of NPs to penetrate tumors and consequently therapies are delivered in a setting that really resembles real-life situations.
Claim 5therapeutic rationalesupports2026Source 1DOIPubMed

RNA-based therapeutics delivered through drug delivery systems offer a highly targeted approach to shutting down oncogenes and drug resistance mechanisms and can complement conventional treatments.

Quoted textsource-backed
Recent advances in RNA-based therapeutics through DDS offer a highly targeted approach to shutting down oncogenes and drug resistance mechanisms, making them a powerful strategy to complement conventional treatments.